Abstract
Background: Tumour necrosis factor α (TNFα) blockade using infliximab, a chimeric anti-TNFα antibody, is an effective treatment for both psoriasis and psoriatic arthritis (PsA).
Objective: To analyse the early effects of infliximab treatment on serial skin and synovial tissue biopsy samples.
Methods: Twelve patients with both active psoriasis and PsA received a single infusion of either infliximab (3 mg/kg) (n = 6) or placebo (n = 6) intravenously. Synovial tissue and lesional skin biopsy specimens were obtained at baseline and 48 hours after treatment. Immunohistochemical analysis was performed to analyse the inflammatory infiltrate. In situ detection of apoptotic cells was performed by TUNEL assay and by immunohistochemical staining with anti-caspase-3 antibodies. Stained tissue sections were evaluated by digital image analysis.
Results: A significant reduction in mean (SEM) T cell numbers was found in both lesional epidermis (baseline 37 (11) cells/mm, 48 hours 26 (11), p = 0.028) and synovial tissue (67 (56) cells/mm2v 32 (30), p = 0.043) after infliximab treatment, but not after placebo treatment (epidermis 18 (8) v 43 (20), NS; synovium 110 (62) v 46 (21), NS). Similarly, the number of macrophages in the synovial sublining was significantly reduced after anti-TNFα treatment (100 (73) v 10 (8), p = 0.043). The changes in cell numbers could not be explained by induction of apoptosis at the site of inflammation.
Conclusions: The effects of anti-TNFα therapy in psoriasis and psoriatic arthritis may be explained by decreased cell infiltration in lesional skin and inflamed synovial tissue early after initiation of treatment.
Full Text
The Full Text of this article is available as a PDF (262.0 KB).
Figure 1.
Representative images of CD3+ immunohistochemical staining and TUNEL assay in lesional psoriatic skin at baseline and 48 hours after initiation of infliximab treatment. Original magnification x400.
Figure 2.
Representative images of CD3+ and CD68+ immunohistochemical staining and TUNEL assay in synovial tissue at baseline and 48 hours after initiation of infliximab treatment. Original magnification x400.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Antoni Christian, Dechant Claudia, Hanns-Martin Lorenz P. D., Wendler Joerg, Ogilvie Alexandra, Lueftl Mathias, Kalden-Nemeth Dolores, Kalden Joachim R., Manger Bernhard. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum. 2002 Oct 15;47(5):506–512. doi: 10.1002/art.10671. [DOI] [PubMed] [Google Scholar]
- Baeten D., Kruithof E., Van den Bosch F., Demetter P., Van Damme N., Cuvelier C., De Vos M., Mielants H., Veys E. M., De Keyser F. Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. Arthritis Rheum. 2001 Jan;44(1):186–195. doi: 10.1002/1529-0131(200101)44:1<186::AID-ANR25>3.0.CO;2-B. [DOI] [PubMed] [Google Scholar]
- Baker B. S., Swain A. F., Fry L., Valdimarsson H. Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br J Dermatol. 1984 May;110(5):555–564. doi: 10.1111/j.1365-2133.1984.tb04678.x. [DOI] [PubMed] [Google Scholar]
- Bata-Csorgo Z., Hammerberg C., Voorhees J. J., Cooper K. D. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J Clin Invest. 1995 Jan;95(1):317–327. doi: 10.1172/JCI117659. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bonifati C., Carducci M., Cordiali Fei P., Trento E., Sacerdoti G., Fazio M., Ameglio F. Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients--relationships with disease severity. Clin Exp Dermatol. 1994 Sep;19(5):383–387. doi: 10.1111/j.1365-2230.1994.tb02687.x. [DOI] [PubMed] [Google Scholar]
- Bos J. D., Hulsebosch H. J., Krieg S. R., Bakker P. M., Cormane R. H. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res. 1983;275(3):181–189. doi: 10.1007/BF00510050. [DOI] [PubMed] [Google Scholar]
- Chaudhari U., Romano P., Mulcahy L. D., Dooley L. T., Baker D. G., Gottlieb A. B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet. 2001 Jun 9;357(9271):1842–1847. doi: 10.1016/s0140-6736(00)04954-0. [DOI] [PubMed] [Google Scholar]
- Costello P. J., Winchester R. J., Curran S. A., Peterson K. S., Kane D. J., Bresnihan B., FitzGerald O. M. Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven. J Immunol. 2001 Feb 15;166(4):2878–2886. doi: 10.4049/jimmunol.166.4.2878. [DOI] [PubMed] [Google Scholar]
- Dolhain R. J., Tak P. P., Dijkmans B. A., De Kuiper P., Breedveld F. C., Miltenburg A. M. Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis. Br J Rheumatol. 1998 May;37(5):502–508. doi: 10.1093/rheumatology/37.5.502. [DOI] [PubMed] [Google Scholar]
- Ellis C. N., Krueger G. G., Alefacept Clinical Study Group Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 2001 Jul 26;345(4):248–255. doi: 10.1056/NEJM200107263450403. [DOI] [PubMed] [Google Scholar]
- Espinoza L. R., Cuéllar M. L., Silveira L. H. Psoriatic arthritis. Curr Opin Rheumatol. 1992 Aug;4(4):470–478. [PubMed] [Google Scholar]
- Ettehadi P., Greaves M. W., Wallach D., Aderka D., Camp R. D. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol. 1994 Apr;96(1):146–151. doi: 10.1111/j.1365-2249.1994.tb06244.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gottlieb A. B., Grossman R. M., Khandke L., Carter D. M., Sehgal P. B., Fu S. M., Granelli-Piperno A., Rivas M., Barazani L., Krueger J. G. Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol. 1992 Mar;98(3):302–309. doi: 10.1111/1523-1747.ep12499782. [DOI] [PubMed] [Google Scholar]
- Gottlieb Alice B., Masud Salman, Ramamurthi Rallapalli, Abdulghani Ahsan, Romano Pat, Chaudhari Umesh, Dooley Lisa T., Fasanmade Adedigbo A., Wagner Carrie L. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol. 2003 Jan;48(1):68–75. doi: 10.1067/mjd.2003.10. [DOI] [PubMed] [Google Scholar]
- Gottlieb S. L., Gilleaudeau P., Johnson R., Estes L., Woodworth T. G., Gottlieb A. B., Krueger J. G. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442–447. doi: 10.1038/nm0595-442. [DOI] [PubMed] [Google Scholar]
- Hommes D. W., van Dullemen H. M., Levi M., van der Ende A., Woody J., Tytgat G. N., van Deventer S. J. Beneficial effect of treatment with a monoclonal anti-tumor necrosis factor-alpha antibody on markers of coagulation and fibrinolysis in patients with active Crohn's disease. Haemostasis. 1997 Nov-Dec;27(6):269–277. doi: 10.1159/000217467. [DOI] [PubMed] [Google Scholar]
- Kraan M. C., Haringman J. J., Ahern M. J., Breedveld F. C., Smith M. D., Tak P. P. Quantification of the cell infiltrate in synovial tissue by digital image analysis. Rheumatology (Oxford) 2000 Jan;39(1):43–49. doi: 10.1093/rheumatology/39.1.43. [DOI] [PubMed] [Google Scholar]
- Kraan Maarten C., Reece Richard J., Smeets Tom J. M., Veale Douglas J., Emery Paul, Tak Paul P. Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: Implications for pathogenesis and evaluation of treatment. Arthritis Rheum. 2002 Aug;46(8):2034–2038. doi: 10.1002/art.10556. [DOI] [PubMed] [Google Scholar]
- Kraan Maarten C., van Kuijk Arno W. R., Dinant Huibert J., Goedkoop Amber Y., Smeets Tom J. M., de Rie Menno A., Dijkmans Ben A. C., Vaishnaw Akshay K., Bos Jan D., Tak Paul P. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum. 2002 Oct;46(10):2776–2784. doi: 10.1002/art.10543. [DOI] [PubMed] [Google Scholar]
- König A., Krenn V., Gillitzer R., Glöckner J., Janssen E., Gohlke F., Eulert J., Müller-Hermelink H. K. Inflammatory infiltrate and interleukin-8 expression in the synovium of psoriatic arthritis--an immunohistochemical and mRNA analysis. Rheumatol Int. 1997;17(4):159–168. doi: 10.1007/s002960050028. [DOI] [PubMed] [Google Scholar]
- Lipsky P. E., van der Heijde D. M., St Clair E. W., Furst D. E., Breedveld F. C., Kalden J. R., Smolen J. S., Weisman M., Emery P., Feldmann M. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000 Nov 30;343(22):1594–1602. doi: 10.1056/NEJM200011303432202. [DOI] [PubMed] [Google Scholar]
- Maini R., St Clair E. W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999 Dec 4;354(9194):1932–1939. doi: 10.1016/s0140-6736(99)05246-0. [DOI] [PubMed] [Google Scholar]
- Mease P. J., Goffe B. S., Metz J., VanderStoep A., Finck B., Burge D. J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000 Jul 29;356(9227):385–390. doi: 10.1016/S0140-6736(00)02530-7. [DOI] [PubMed] [Google Scholar]
- Moreland L. W., Schiff M. H., Baumgartner S. W., Tindall E. A., Fleischmann R. M., Bulpitt K. J., Weaver A. L., Keystone E. C., Furst D. E., Mease P. J. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999 Mar 16;130(6):478–486. doi: 10.7326/0003-4819-130-6-199903160-00004. [DOI] [PubMed] [Google Scholar]
- Ogilvie A. L., Antoni C., Dechant C., Manger B., Kalden J. R., Schuler G., Lüftl M. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol. 2001 Mar;144(3):587–589. doi: 10.1046/j.1365-2133.2001.04089.x. [DOI] [PubMed] [Google Scholar]
- Oh C. J., Das K. M., Gottlieb A. B. Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol. 2000 May;42(5 Pt 1):829–830. doi: 10.1067/mjd.2000.105948. [DOI] [PubMed] [Google Scholar]
- Partsch G., Steiner G., Leeb B. F., Dunky A., Bröll H., Smolen J. S. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol. 1997 Mar;24(3):518–523. [PubMed] [Google Scholar]
- Present D. H., Rutgeerts P., Targan S., Hanauer S. B., Mayer L., van Hogezand R. A., Podolsky D. K., Sands B. E., Braakman T., DeWoody K. L. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999 May 6;340(18):1398–1405. doi: 10.1056/NEJM199905063401804. [DOI] [PubMed] [Google Scholar]
- Reece R. J., Canete J. D., Parsons W. J., Emery P., Veale D. J. Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritis Rheum. 1999 Jul;42(7):1481–1484. doi: 10.1002/1529-0131(199907)42:7<1481::AID-ANR23>3.0.CO;2-E. [DOI] [PubMed] [Google Scholar]
- Ritchlin C., Haas-Smith S. A., Hicks D., Cappuccio J., Osterland C. K., Looney R. J. Patterns of cytokine production in psoriatic synovium. J Rheumatol. 1998 Aug;25(8):1544–1552. [PubMed] [Google Scholar]
- Sandborn W. J., Hanauer S. B., Katz S., Safdi M., Wolf D. G., Baerg R. D., Tremaine W. J., Johnson T., Diehl N. N., Zinsmeister A. R. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001 Nov;121(5):1088–1094. doi: 10.1053/gast.2001.28674. [DOI] [PubMed] [Google Scholar]
- Smeets Tom J. M., Kraan Maarten C., van Loon Marieke E., Tak Paul-Peter. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum. 2003 Aug;48(8):2155–2162. doi: 10.1002/art.11098. [DOI] [PubMed] [Google Scholar]
- Smolen J. S., Breedveld F. C., Eberl G., Jones I., Leeming M., Wylie G. L., Kirkpatrick J. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum. 1995 Jan;38(1):38–43. doi: 10.1002/art.1780380106. [DOI] [PubMed] [Google Scholar]
- Tak P. P., Taylor P. C., Breedveld F. C., Smeets T. J., Daha M. R., Kluin P. M., Meinders A. E., Maini R. N. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum. 1996 Jul;39(7):1077–1081. doi: 10.1002/art.1780390702. [DOI] [PubMed] [Google Scholar]
- Tak P. P., van der Lubbe P. A., Cauli A., Daha M. R., Smeets T. J., Kluin P. M., Meinders A. E., Yanni G., Panayi G. S., Breedveld F. C. Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. Arthritis Rheum. 1995 Oct;38(10):1457–1465. doi: 10.1002/art.1780381012. [DOI] [PubMed] [Google Scholar]
- Taylor P. C., Peters A. M., Paleolog E., Chapman P. T., Elliott M. J., McCloskey R., Feldmann M., Maini R. N. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum. 2000 Jan;43(1):38–47. doi: 10.1002/1529-0131(200001)43:1<38::AID-ANR6>3.0.CO;2-L. [DOI] [PubMed] [Google Scholar]
- Van den Brande Jan M. H., Braat Henri, van den Brink Gijs R., Versteeg Henri H., Bauer Christiaan A., Hoedemaeker Inge, van Montfrans Catherine, Hommes Daan W., Peppelenbosch Maikel P., van Deventer Sander J. H. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 2003 Jun;124(7):1774–1785. doi: 10.1016/s0016-5085(03)00382-2. [DOI] [PubMed] [Google Scholar]
- Veale D., Yanni G., Rogers S., Barnes L., Bresnihan B., Fitzgerald O. Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum. 1993 Jul;36(7):893–900. doi: 10.1002/art.1780360705. [DOI] [PubMed] [Google Scholar]
- Wollina U., Konrad H. Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis factor-alpha antibody. J Eur Acad Dermatol Venereol. 2002 Mar;16(2):127–129. doi: 10.1046/j.1468-3083.2002.00391.x. [DOI] [PubMed] [Google Scholar]
- ten Hove T., van Montfrans C., Peppelenbosch M. P., van Deventer S. J. H. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut. 2002 Feb;50(2):206–211. doi: 10.1136/gut.50.2.206. [DOI] [PMC free article] [PubMed] [Google Scholar]
- van Dullemen H. M., van Deventer S. J., Hommes D. W., Bijl H. A., Jansen J., Tytgat G. N., Woody J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995 Jul;109(1):129–135. doi: 10.1016/0016-5085(95)90277-5. [DOI] [PubMed] [Google Scholar]